Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
AbbVie Inc.
ABBVHealth technology
$394.1B
Market Cap
Shariah Analysis
Failed
Business
Cash
Liabilities
Based on AAOIFI screening standards, AbbVie Inc. appears to be Failed.
Business Activity
FYE 2024
Non-Permissible Income (<5%)5.60%
Non-Permissible
$3.4B
Total Income
$60.2B
Revenue Breakdown
Humira
$9B
Skyrizi
$11.7B
Rinvoq
$6B
Oncology
$3.3B
Venclexta
$2.6B
Elahere
$479M
Epkinly
$146M
Botox Cosmetic
$2.7B
Non-Compliant: $2.7B
Juvederm
$1.2B
Botox Therapeutic
$3.3B
Vraylar
$3.3B
Duodopa
$447M
Ubrelvy
$1B
Qulipta
$658M
Ozurdex
$494M
Lumigan/Ganfort
$429M
Other Aesthetics
$1.3B
Other Neuroscience
$338M
Alphagan/Combigan
$248M
Restasis
$224M
Other Eye Care
$847M
Mavyret
$1.3B
Creon
$1.4B
Linzess/Constella
$954M
All other
$3B
Interest income
Non-Operating
$648M
Non-Compliant: $648M
Other expense, net
Non-Operating
$3.2B
Financial Screening
FYE 2024
Cash (<30%)1.83%
Non-Shariah Cash Items
Cash And Cash Equivalents$5.5B
Other Short Term Investments$31M
Liabilities (<30%)22.15%
Non-Shariah Liabilities
Long Term Debt$60.3B
Current Debt$6.8B
Market Data
Exchange
NYSE
CurrencyUSD
CountryUnited States
Last Updated2025-12-19
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
NYSE
